Innovation in interventional cardiology

New Xience Skypoint stent

Dr. José R. Rumoroso

02/11/2021

Xience Skypoint stent

2021 continues with more new launches. In this case, it is the new Xience Skypoint stent (Abbott, USA), which has just been brought to market. This is a drug-eluting stent with improvements that provide excellent navigability, as well as greater post-dilation ranges to allow treatment any type of lesion and vessel.

Xience Skypoint has maintained many of the features of the Xience family. The stent design is of an everolimus-eluting cobalt-chromium multi-link platform; its fluoropolymer coating confers exceptional clinical outcomes in terms of stent thrombosis, and it also maintains the CE mark for 1 month of dual antiplatelet therapy in patients with high bleeding risk, offering the safest stent for all indications.

Xience Skypoint has a wider expansion range than the previous Xience generation, up to 5.75 mm diameter even with a length of 48 mm. This allows for greater expansion of the stent without longitudinal shortening, which improves precision in its positioning.

Other important changes in the device are the following: a more ergonomic connector port, with the largest stent dimensions, a slimmer catheter with a seamless one-piece shaft and a slimmer profile that guarantees high pushability with minimal force, facilitating its navigability in the treatment of more challenging lesions.

Keywords: Percutaneous coronary intervention, coronary stent.

Save
Cookies user prefences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline